{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:25:12Z","timestamp":1780097112166,"version":"3.54.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":3197,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Extent of cardiac sympathetic activation can be estimated from physiological parameters, blood biomarkers, and imaging findings. This study examined the prognostic value of three markers of sympathetic activity and their relationship to beta blocker dose in heart failure patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A post hoc analysis of 858 heart failure subjects in the ADMIRE-HF trial was performed. Variables related to sympathetic activity were plasma norepinephrine, baseline heart rate, the heart to mediastinum (H\/M) ratio of 123I-mIBG uptake, and beta blocker dose. Univariate and multivariate analyses for occurrence of mortality (all-cause and cardiac) and arrhythmic events were performed. Beta blocker dose was significantly related to age, heart rate, b-type natriuretic peptide (negatively), body mass index, body weight and plasma norepinephrine. Univariate predictors of all-cause and cardiac mortality were baseline heart rate (\u03c72 = 4.5, P = 0.029 and \u03c72 = 5 .2, P = 0.022, respectively), plasma norepinephrine level (\u03c72 = 8.9, P = 0.0006 and \u03c72 = 8.6, P = 0.003, respectively), and H\/M (\u03c7 = 22.4, P &amp;lt; 0.0001 and \u03c72 = 17.8, P &amp;lt; 0.0001, respectively). In multivariate analyses, carvedilol-equivalent dose (P = 0.017), plasma norepinephrine (P = 0.002), and H\/M (P = 0.0001) were significant predictors of all-cause mortality. In separate analyses using multiple measurements of heart rate, mean heart rate &amp;gt;67 b.p.m. was associated with significantly higher cardiac mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher beta blocker dose was associated with lower mortality, but of the variables associated with sympathetic activity examined, cardiac 123I-mIBG uptake was the most powerful prognostic marker in heart failure patients. Elevated heart rate was associated with greater risk for cardiac death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12153","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:21:05Z","timestamp":1492647665000},"page":"499-506","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Beta Blocker dose and Markers of Sympathetic Activation in Heart Failure Patients: Interrelationships and Prognostic Significance"],"prefix":"10.1093","volume":"4","author":[{"given":"Alain","family":"Cohen-Solal","sequence":"first","affiliation":[{"name":"UMR-S 942, Paris Diderot University, FIRE DHU, Lariboisiere Hospital, Assistance Publique \u2013 Hopitaux de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold F.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Diagram Consulting , Kihei, HI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana L.","family":"Pi\u00f1a","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Albert Einstein College of Medicine, Montefiore Medical Center , Bronx, New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"key":"2026012115152298300_ehf212153-bib-0001","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pcad.2008.01.003","article-title":"The role of the autonomic nervous system in sudden cardiac death","volume":"50","author":"Vaseghi","year":"2008","journal-title":"Prog Cardiovasc Dis"},{"key":"2026012115152298300_ehf212153-bib-0002","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1055\/s-2004-817725","article-title":"Testing the autonomic nervous system","volume":"23","author":"Low","year":"2003","journal-title":"Semin Neurol"},{"key":"2026012115152298300_ehf212153-bib-0003","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00001573-200401000-00003","article-title":"Autonomic aspects of arrhythmogenesis: The enduring and the new","volume":"19","author":"Verrier","year":"2004","journal-title":"Curr Opin Cardiol"},{"key":"2026012115152298300_ehf212153-bib-0004","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJM196209272671305","article-title":"Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure","volume":"267","author":"Chidsey","year":"1962","journal-title":"N Engl J Med"},{"key":"2026012115152298300_ehf212153-bib-0005","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","article-title":"Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure","volume":"311","author":"Cohn","year":"1984","journal-title":"N Engl J Med"},{"key":"2026012115152298300_ehf212153-bib-0006","doi-asserted-by":"crossref","first-page":"7L","DOI":"10.1016\/S0002-9149(97)00844-8","article-title":"Adrenergic nervous system in heart failure","volume":"80","author":"Esler","year":"1997","journal-title":"Am J Cardiol"},{"key":"2026012115152298300_ehf212153-bib-0007","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0735-1097(95)00332-0","article-title":"Adverse consequences of high sympathetic nervous activity in the failing human heart","volume":"26","author":"Kaye","year":"1995","journal-title":"J Amer Coll Cardiol"},{"key":"2026012115152298300_ehf212153-bib-0008","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Ford I; SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose?: Findings from the shift (systolic heart failure treatment with the i(f) inhibitor ivabradine trial) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Amer Coll Cardiol"},{"key":"2026012115152298300_ehf212153-bib-0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: Analysis from the shift study","volume":"102","author":"Bohm","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2026012115152298300_ehf212153-bib-0010","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/S0002-9149(99)00145-9","article-title":"Cardiac sympathetic activity as measured by myocardial 123-i- metaiodobenzylguanidine uptake and heart rate variability in idiopathic dilated cardiomyopathy","volume":"83","author":"Lotze","year":"1999","journal-title":"Am J Cardiol"},{"key":"2026012115152298300_ehf212153-bib-0011","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","article-title":"2009 focused update: Accf\/aha guidelines for the diagnosis and management of heart failure in adults: A report of the american college of cardiology foundation\/american heart association task force on practice guidelines: Developed in collaboration with the international society for heart and lung transplantation","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation"},{"key":"2026012115152298300_ehf212153-bib-0012","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (hfa) of the esc","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012115152298300_ehf212153-bib-0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejheart.2006.07.007","article-title":"International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: Data from the euroheart failure survey","volume":"9","author":"Lainscak","year":"2007","journal-title":"Eur J Heart Failure"},{"key":"2026012115152298300_ehf212153-bib-0014","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurjhf\/hfr020","article-title":"Titration to target dose of bisoprolol vs. Carvedilol in elderly patients with heart failure: The cibis-eld trial","volume":"13","author":"Dungen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026012115152298300_ehf212153-bib-0015","first-page":"2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Mocha investig Circ"},{"key":"2026012115152298300_ehf212153-bib-0016","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: Beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026012115152298300_ehf212153-bib-0017","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/eurjhf\/hfs189","article-title":"Heart failure of the French society of cardiology. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: The ofica study","volume":"15","author":"Logeart","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026012115152298300_ehf212153-bib-0018","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.jacc.2010.01.014","article-title":"Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (adreview myocardial imaging for risk evaluation in heart failure) study","volume":"55","author":"Jacobson","year":"2010","journal-title":"J Amer Coll Cardiol"},{"key":"2026012115152298300_ehf212153-bib-0019","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacc.2012.03.023","article-title":"Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: Results from the HF-action (heart failure: A controlled trial investigating outcomes of exercise training) trial","volume":"60","author":"Fiuzat","year":"2012","journal-title":"J Amer Coll Cardiol"},{"key":"2026012115152298300_ehf212153-bib-0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/07853890410017467","article-title":"Cardiac cachexia","volume":"36","author":"Anker","year":"2004","journal-title":"Ann Med"},{"key":"2026012115152298300_ehf212153-bib-0021","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0195-668X(02)00743-1","article-title":"Bisoprolol dose-response relationship in patients with congestive heart failure: A subgroup analysis in the cardiac insufficiency bisoprolol study(cibis ii)","volume":"24","author":"Simon","year":"2003","journal-title":"Eur Heart J"},{"key":"2026012115152298300_ehf212153-bib-0022","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0735-1097(02)01970-8","article-title":"Dose of metoprolol cr\/xl and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol cr\/xl randomized intervention trial in chronic heart failure (merit-hf)","volume":"40","author":"Wikstrand","year":"2002","journal-title":"J Amer Coll Cardiol"},{"key":"2026012115152298300_ehf212153-bib-0023","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ahj.2007.03.025","article-title":"Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: Data from the study of the effects of nebivolol intervention on outcomes and rehospitalisation in seniors with heart failure (seniors) trial","volume":"154","author":"Dobre","year":"2007","journal-title":"Amer Heart J"},{"issue":"82","key":"2026012115152298300_ehf212153-bib-0024","article-title":"Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: An analysis from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (optimize-hf)","volume":"153","author":"Fonarow","year":"2007","journal-title":"Amer Heart J"},{"key":"2026012115152298300_ehf212153-bib-0025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0735-1097(98)00608-1","article-title":"Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: Relationship with peak oxygen uptake and prognosis","volume":"33","author":"Cohen-Solal","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"2026012115152298300_ehf212153-bib-0026","first-page":"917","article-title":"Prognostic value of mibg imaging in idiopathic dilated cardiomyopathy","volume":"40","author":"Merlet","year":"1999","journal-title":"J Nucl Med"},{"key":"2026012115152298300_ehf212153-bib-0027","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jcmg.2013.02.007","article-title":"A pooled analysis of multicenter cohort studies of I-123-mIBG cardiac sympathetic innervation imaging for assessment of long-term prognosis in chronic heart failure","volume":"6","author":"Nakata","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115152298300_ehf212153-bib-0028","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/ehjci\/jeu044","article-title":"For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with heart failure? Results of a pooled individual patient data meta-analysis","volume":"15","author":"Verschure","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012115152298300_ehf212153-bib-0029","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2967\/jnumed.115.156406","article-title":"I-123 mIBG imaging for prediction of mortality and potentially fatal events in heart failure: The ADMIRE-HFX study","volume":"56","author":"Narula","year":"2015","journal-title":"J Nucl Med"},{"key":"2026012115152298300_ehf212153-bib-0030","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s12350-012-9603-0","article-title":"Selective improvement in Seattle heart failure model risk stratification using Iodine-123 meta-iodobenzylguanidine imaging","volume":"19","author":"Ketchum","year":"2012","journal-title":"J Nucl Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12153","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/4\/4\/499\/66256046\/eschf_4_4_499.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/4\/4\/499\/66256046\/eschf_4_4_499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:20:46Z","timestamp":1769026846000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/4\/4\/499\/8413362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,19]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12153","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11]]},"published":{"date-parts":[[2017,4,19]]},"assertion":[{"value":"2015-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}